Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients

Daclizumab was approved by the FDA and the EMA in 2016 for the treatment of relapsing forms of multiple sclerosis (MS). Cases of severe inflammatory brain disease with fatal outcome led to the withdrawal of approval in Europe and the US on March 2, 2018. Approximately 8,000 patients worldwide receiv...

Full description

Bibliographic Details
Main Authors: Paulus S. Rommer, Klaus Berger, David Ellenberger, Firas Fneish, Alexandra Simbrich, Alexander Stahmann, Uwe K. Zettl
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
multiple sclerosis—drug therapy
daclizumab
side effects
registers
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00996/full

Similar Items

Similar Items